These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 14602743)

  • 21. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.
    Patel K; Coffler MS; Dahan MH; Malcom PJ; Deutsch R; Chang RJ
    Clin Endocrinol (Oxf); 2004 Jan; 60(1):67-74. PubMed ID: 14678290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.
    Koivunen RM; Morin-Papunen LC; Ruokonen A; Tapanainen JS; Martikainen HK
    Hum Reprod; 2001 Dec; 16(12):2546-51. PubMed ID: 11726572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment.
    Mehta RV; Patel KS; Coffler MS; Dahan MH; Yoo RY; Archer JS; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2136-41. PubMed ID: 15644405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion.
    Patel K; Coffler MS; Dahan MH; Yoo RY; Lawson MA; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5456-61. PubMed ID: 14602789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
    Blank SK; McCartney CR; Helm KD; Marshall JC
    Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance.
    Ulloa-Aguirre A; Portocarrero L; Zariñán T; Olivares A; Carranza-Lira S; Veldhuis JD; López-Alvarenga JC
    Reprod Biomed Online; 2006 Jun; 12(6):669-83. PubMed ID: 16792841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
    Judd HL; Rigg LA; Anderson DC; Yen SS
    J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP; Lu JK; Chang RJ
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.